Phase 4Recruiting
CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS
A Multicenter, Randomized Controlled Comparison of Effect of Evolocumab Versus Standard Lipid Lowering Therapy on Plaque Progression in Patients With Acute Coronary Syndrome by Serial PCCT (CAPRA-EVO Trial)
- Sponsor
- West China Hospital (Academic or other)
- Enrolment
- 232 planned
- Conditions
- Coronary; Coronary Artery Disease
- Interventions
- Evolocumab; Serial photon-counting coronary computed tomography angiography; Standard Lipid-Lowering Therapy
- Ages
- adults, older adults
- Registry
- NCT07612774
From the registry
The CAPRA-EVO trial is a single-center, randomized, open-label study with blinded endpoint assessment comparing early evolocumab plus standard lipid-lowering therapy versus standard-of-care lipid-lowering therapy in patients with acute coronary syndrome after successful percutaneous coronary intervention. The study will use serial photon-counting coronary computed tomography angiography at baseline and 52 weeks to assess changes in non-culprit coronary plaque burden and stenosis severity. Secondary outcomes include changes in high-risk plaque features, lipid and inflammatory biomarkers, cardiovascular events, and safety outcomes. The trial aims to determine whether early intensive LDL-C lowering with evolocumab can reduce coronary plaque progression and support PCCT-CCTA as a noninvasive tool for monitoring atherosclerotic plaque dynamics.
Primary outcomes
- Total atherosclerotic volume and stenosis severity
- b. Stenosis severity at the target lesion level (defined as luminal stenosis ≥50%, particularly in left main coronary artery [LMCA] or proximal left anterior descending artery [LAD] OR presence of ≥2 high-risk plaque features)